» Articles » PMID: 11689198

The Inhibition of Gluconeogenesis by Chloroquine Contributes to Its Hypoglycaemic Action

Overview
Journal Eur J Pharmacol
Specialty Pharmacology
Date 2001 Nov 2
PMID 11689198
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The effect of chloroquine on gluconeogenesis in isolated hepatocytes and kidney-cortex tubules of rabbit has been studied. The inhibitory action of 200 microM chloroquine was the highest in hepatocytes and renal tubules incubated with glutamine and glutamate+glycerol+octanoate, respectively, while in the presence of other substrates the drug action was less pronounced. With amino acids as substrates, the inhibition of gluconeogenesis was accompanied by a decreased glutamine production, resulting from a decline of glutamate dehydrogenase activity. A decrease in the urea production by hepatocytes incubated with chloroquine in the presence of glutamine but not NH4Cl as the source of ammonium is in agreement with this suggestion. The degree of inhibition by chloroquine of the rate of gluconeogenesis in renal tubules isolated from control rabbits was similar to that determined in diabetic animals. Chloroquine-induced changes in levels of intracellular gluconeogenic intermediates indicate a decrease in phosphoenolpyruvate carboxykinase and glucose-6-phosphatase activities probably due to increased concentration of 2-oxoglutarate, an inhibitor of these two enzymes. In view of the data, it is likely that inhibition by chloroquine of glucose formation in liver and kidney may contribute to the hypoglycaemic action of this drug. The importance of the inhibitory effect of chloroquine on glutamate dehydrogenase activity in the antihyperglycaemic action of the drug is discussed.

Citing Articles

Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives.

Carosi F, Broseghini E, Fabbri L, Corradi G, Gili R, Forte V Cancers (Basel). 2024; 16(15).

PMID: 39123479 PMC: 11311780. DOI: 10.3390/cancers16152752.


A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with -Mutated Solid Tumors.

Khurshed M, Molenaar R, van Linde M, Mathot R, Struys E, van Wezel T Cancers (Basel). 2021; 13(10).

PMID: 34069550 PMC: 8161333. DOI: 10.3390/cancers13102474.


Chloroquine differentially modulates coronary vasodilation in control and diabetic mice.

Zhang Q, Tsuji-Hosokawa A, Willson C, Watanabe M, Si R, Lai N Br J Pharmacol. 2019; 177(2):314-327.

PMID: 31503328 PMC: 6989957. DOI: 10.1111/bph.14864.


Re-purposing Chloroquine for Glioblastoma: Potential Merits and Confounding Variables.

Weyerhauser P, Kantelhardt S, Kim E Front Oncol. 2018; 8:335.

PMID: 30211116 PMC: 6120043. DOI: 10.3389/fonc.2018.00335.


H-ATPase blockade reduced renal gluconeogenesis and plasma glucose in a diabetic rat model.

Tojo A, Hatakeyama S, Nangaku M, Ishimitsu T Med Mol Morphol. 2018; 51(2):89-95.

PMID: 29318388 PMC: 5960008. DOI: 10.1007/s00795-017-0175-6.